Fulcrum Therapeutics(FULC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The 20-milligram cohort of the phase 1b PIONEER trial showed a mean absolute increase in fetal hemoglobin (HbF) of 12.2%, rising from a baseline of 7.1% to 19.3% at week 12 [6][13] - Total hemoglobin increased by more than 1 gram per deciliter after 12 weeks of treatment [7][18] - A reduction of 34% in lactate dehydrogenase (LDH) and 40% in indirect bilirubin was observed, indicating decreased hemolysis [16] Business Line Data and Key Metrics Changes - The 20-milligram cohort demonstrated that over half of the patients achieved HbF levels at or above 20%, which is historically associated with clinically meaningful protection [6][8] - The cohort consisted of 12 evaluable patients, with 7 reporting no vaso-occlusive crises (VOCs) during the treatment period [7][19] Market Data and Key Metrics Changes - The unmet medical need for sickle cell disease treatments remains significant, with mortality rates elevated and life expectancy reduced despite advances in clinical care [9] - The 20-milligram cohort included patients from Nigeria, reflecting a more heterogeneous population compared to previous cohorts [37] Company Strategy and Development Direction - The company plans to provide an update on the next trial design in Q2 2026 and aims to initiate a potential registration-enabling trial in the second half of 2026 [30] - The strategy includes engaging with the European Medicines Agency for protocol assistance and feedback on the next trial [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pociredir to significantly reduce acute vaso-occlusive events and hemolytic anemia in sickle cell disease patients [24][29] - The company believes it has a two-year head start over competitors in the market for fetal hemoglobin-inducing agents [76] Other Important Information - Pociredir continues to be generally well-tolerated at the 20-milligram dose, with no treatment-related serious adverse events reported [19][20] - The company has dosed almost 150 adults to date, with no dose-limiting toxicities observed [20] Q&A Session Summary Question: Can you provide additional insight into the VOCs and when they occurred during the study? - VOCs were spread throughout the treatment period, with more occurring in patients with lower increases in HbF [34] Question: How well does the 20-milligram cohort represent the population of sickle cell patients? - The cohort is likely more representative of the global population, with a more heterogeneous haplotype distribution [37] Question: Which biomarkers might take longer to show a clearer dose response? - Markers of hemolysis, such as LDH and bilirubin, may take longer to reflect the full effects of HbF induction [41][44] Question: How will the company approach the meeting with the FDA regarding the registrational trial? - The company plans to discuss the robust data supporting HbF induction and its association with improved clinical outcomes [50] Question: What is the degree of unmet need in sickle cell disease? - The unmet need is significant, with hydroxyurea being the only established treatment, and many patients continue to experience severe events despite treatment [85]